Skip to main content

The Globe and Mail

Iceland's Actavis launches unsolicited bid for Pliva

Iceland's Actavis Group HF launched an unsolicited $1.6-billion (U.S.) bid for Croatian drug firm Pliva d.d. yesterday in a deal it said would create the world's third largest generic drugs firm. The bid -- the latest in a wave of consolidation sweeping the sector -- values Pliva at 570 Croatian kuna per share ($94.53 U.S.), a premium of 35 per cent over the average share price during the last three months, Actavis said. Pliva's management said it considered the offer "unattractive." Pliva is Eastern Europe's leading drugs producer by sales. ACT (Reykjavik) rose .90 krona to 60.10 kronur (87 cents U.S.). PLVARA (Zagreb) rose 31 kuna to 541 kuna ($89.67 U.S.). Reuters

Report an error Licensing Options

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Globe Newsletters

Get a summary of news of the day

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at